Skip to main content

Leitat and the Association of Surveyors promote innovation in construction

By 6 de April de 2011November 18th, 2020No Comments
< Back to news

Leitat and the Association of Surveyors promote innovation in construction

The Association of Surveyors, Architects and Engineers Building Technology Centre of Barcelona and Leitat signed on Wednesday 30 March, an agreement of collaboration will allow both organizations to jointly develop activities to increase and promote research, development and innovation in the field of construction, to contribute to improving the competitiveness of businesses and professionals. The signing of this framework agreement took place on Wednesday 30 March at the facilities of the Technological Center of Leitat Terrace. Participated Eusebi Cima, president of Maria Rosa Leitat and whirlpool, president of the Builders Association of Barcelona.

Both institutions will unite their efforts to advance the construction sector in the way of innovation and sustainability. To do so, carried out actions aimed at contributing to the increased competitiveness of companies and professionals in the sector, identify opportunities in the field of innovation by setting up R & D in collaboration with businesses and promote the realization of activities for the diffusion of innovation in construction processes, enhancing the culture of industrial innovation.

The Technology Centre Leitat, meanwhile, is a Technology Centre, a member of TECNIO and recognized by the Ministry of Science and Innovation, which aims to collaborate with companies and institutions adding technological value to both products and processes and bases its work on research, development and innovation.

The Leitat Biomed Division of Leitat –located at Barcelona Science Park– is composed of a team of professionals with over 15 years experience in the field of basic and applied cancer research in the field of the pharmaceutical industry. Some of the drugs previously generated and developed by members of this team are currently in phase III, II and I cancer clinical trials.